Gyre Therapeutics (NASDAQ:GYRE) Shares Gap Down to $15.41

Gyre Therapeutics, Inc. (NASDAQ:GYREGet Free Report)’s stock price gapped down prior to trading on Friday . The stock had previously closed at $15.41, but opened at $14.95. Gyre Therapeutics shares last traded at $15.22, with a volume of 5,521 shares trading hands.

Gyre Therapeutics Stock Up 0.6 %

The company has a market cap of $1.32 billion, a PE ratio of -0.75 and a beta of 2.11. The firm’s fifty day simple moving average is $17.39.

Hedge Funds Weigh In On Gyre Therapeutics

A hedge fund recently bought a new stake in Gyre Therapeutics stock. Northern Trust Corp purchased a new stake in Gyre Therapeutics, Inc. (NASDAQ:GYREFree Report) during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 24,614 shares of the company’s stock, valued at approximately $632,000. Northern Trust Corp owned approximately 0.97% of Gyre Therapeutics as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 23.99% of the company’s stock.

About Gyre Therapeutics

(Get Free Report)

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.

See Also

Receive News & Ratings for Gyre Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gyre Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.